公开(公告)号：CA2233550C

公开(公告)日：2010-06-22

申请号：CA2233550

申请日：1996-09-25

Applicant: ABBOTT LAB

Inventor： BROOKS CLINT D W ,  BHATIA PRAMILA ,  KOLASA THEODOZYJ ,  STEWART ANDREW O ,  GUNN DAVID E ,  CRAIG RICHARD A

IPC: C07D215/14 ,  C07D239/26 ,  A61K31/41 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/454 ,  A61K31/47 ,  A61K31/495 ,  A61K31/498 ,  A61K31/506 ,  A61P37/08 ,  A61P43/00 ,  C07D213/30 ,  C07D213/55 ,  C07D215/18 ,  C07D235/12 ,  C07D235/20 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/30 ,  C07D277/64 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14

Abstract: Compounds having formula (I), wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, haloalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d) -NR6SO2R9, (e) -NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.

公开(公告)号：PT862557E

公开(公告)日：2003-04-30

申请号：PT96932335

申请日：1996-09-25

Applicant: ABBOTT LAB

Inventor： BHATIA PRAMILA ,  CRAIG RICHARD A ,  BROOKS CLINT D W ,  KOLASA THEODOZYJ ,  STEWART ANDREW O ,  GUNN DAVID E

IPC: C07D239/26 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/4402 ,  A61K31/454 ,  A61K31/47 ,  A61K31/498 ,  A61K31/506 ,  A61P37/08 ,  A61P43/00 ,  C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14 ,  A61K31/395

Abstract: Compounds having the formula: wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d)-NR6SO2R9, (e)-NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.

公开(公告)号：DE69625080T2

公开(公告)日：2003-10-09

申请号：DE69625080

申请日：1996-09-25

Applicant: ABBOTT LAB

Inventor： BROOKS CLINT D W ,  BHATIA PRAMILA ,  KOLASA THEODOZYJ ,  STEWART ANDREW O ,  GUNN DAVID E ,  CRAIG RICHARD A

IPC: C07D239/26 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/4402 ,  A61K31/454 ,  A61K31/47 ,  A61K31/498 ,  A61K31/506 ,  A61P37/08 ,  A61P43/00 ,  C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14 ,  A61K31/395

Abstract: Compounds having the formula: wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d)-NR6SO2R9, (e)-NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.

公开(公告)号：AT228504T

公开(公告)日：2002-12-15

申请号：AT96932335

申请日：1996-09-25

Applicant: ABBOTT LAB

Inventor： BROOKS CLINT D W ,  BHATIA PRAMILA ,  KOLASA THEODOZYJ ,  STEWART ANDREW O ,  GUNN DAVID E ,  CRAIG RICHARD A

IPC: C07D239/26 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/4402 ,  A61K31/454 ,  A61K31/47 ,  A61K31/498 ,  A61K31/506 ,  A61P37/08 ,  A61P43/00 ,  C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14 ,  A61K31/395

Abstract: Compounds having the formula: wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d)-NR6SO2R9, (e)-NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.

公开(公告)号：AU711352B2

公开(公告)日：1999-10-14

申请号：AU7118296

申请日：1996-09-25

Applicant: ABBOTT LAB

Inventor： BROOKS CLINT D W ,  BHATIA PRAMILA ,  KOLASA THEODOZYJ ,  STEWART ANDREW O ,  GUNN DAVID E ,  CRAIG RICHARD A

IPC: C07D239/26 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/4402 ,  A61K31/454 ,  A61K31/47 ,  A61K31/498 ,  A61K31/506 ,  A61P37/08 ,  A61P43/00 ,  C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14 ,  A61K31/395

Abstract: Compounds having the formula: wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d)-NR6SO2R9, (e)-NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.

公开(公告)号：AU7370096A

公开(公告)日：1997-04-28

申请号：AU7370096

申请日：1996-09-25

Applicant: ABBOTT LAB

Inventor： BROOKS CLINT D W ,  BHATIA PRAMILA ,  KOLASA THEODOZYJ

IPC: C07D213/30 ,  C07D213/36 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D239/26 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14 ,  A61K31/395

公开(公告)号：AU7165196A

公开(公告)日：1997-04-28

申请号：AU7165196

申请日：1996-09-24

Applicant: ABBOTT LAB

Inventor： BROOKS CLINT D W ,  BHATIA PRAMILA ,  KOLASA THEODOZYJ

IPC: C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D239/26 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14 ,  A61K31/47 ,  A61K31/44 ,  C07D277/62 ,  A61K31/425 ,  A61K31/42 ,  C07D235/20 ,  A61K31/415 ,  A61K31/495 ,  A61K31/505 ,  C07D417/04

Abstract: Compounds having the formula: or a pharmaceutically acceptable salt thereof wherein W and Y at each occurrence are the same and W is selected from the group consisting of optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; Y is selected from optionally substituted phenylene and optionally substituted to six carbon atoms; A is selected from alkylene, alkenylene, cycloalkylene, and optionally substituted wherein the alkylene portion is of one to six carbon atoms; and M is selected from hydrogen, a pharmaceutically acceptable cation, a pharmaceutically acceptable, metabolically cleavable group, -OR3, and -NR4R5, inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis in a mammal.

公开(公告)号：CA2233550A1

公开(公告)日：1997-04-10

申请号：CA2233550

申请日：1996-09-25

Applicant: ABBOTT LAB

Inventor： BROOKS CLINT D W ,  GUNN DAVID E ,  STEWART ANDREW O ,  CRAIG RICHARD A ,  KOLASA THEODOZYJ ,  BHATIA PRAMILA

IPC: C07D239/26 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/4402 ,  A61K31/454 ,  A61K31/47 ,  A61K31/498 ,  A61K31/506 ,  A61P37/08 ,  A61P43/00 ,  C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14 ,  C07D401/14 ,  C07D413/14 ,  C07D235/20 ,  C07D277/30 ,  A61K31/41 ,  A61K31/44 ,  A61K31/495 ,  C07D213/55

Abstract: Compounds having formula (I), wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, haloalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) OR6, (c) -NR7R8, (d) -NR6SO2R9, (e) -NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.

公开(公告)号：ZA9500555B

公开(公告)日：1996-02-06

申请号：ZA9500555

申请日：1995-01-24

Applicant: ABBOTT LAB

Inventor： KOLASA THEODOZYJ ,  BHATIA PRAMILA ,  BROOKS DEE W

IPC: C07D401/12 ,  C07D417/12 ,  C07D

CPC classification number: C07D401/12 ,  C07D417/12

公开(公告)号：ES2188788T3

公开(公告)日：2003-07-01

申请号：ES96932335

申请日：1996-09-25

Applicant: ABBOTT LAB

Inventor： BROOKS CLINT D W ,  BHATIA PRAMILA ,  KOLASA THEODOZYJ ,  STEWART ANDREW O ,  GUNN DAVID E ,  CRAIG RICHARD A

IPC: C07D239/26 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/4402 ,  A61K31/454 ,  A61K31/47 ,  A61K31/498 ,  A61K31/506 ,  A61P37/08 ,  A61P43/00 ,  C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14 ,  A61K31/395

Abstract: Compounds having the formula: wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d)-NR6SO2R9, (e)-NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.